XBiotech Inc. (NASDAQ:XBIT) saw strong trading volume on Friday . 213,374 shares changed hands during trading, an increase of 29% from the previous session’s volume of 164,780 shares.The stock last traded at $13.50 and had previously closed at $14.26.

A number of equities research analysts have weighed in on the company. Noble Financial restated a “buy” rating and set a $24.00 price target on shares of XBiotech in a research report on Thursday, May 19th. Zacks Investment Research upgraded XBiotech from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a report on Tuesday, May 24th.

The company’s market cap is $424.34 million. The company has a 50-day moving average of $15.14 and a 200-day moving average of $13.16.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.